BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans RO, Struck J, Schulte J, Hillege HL, van der Harst P, Peelen LM, Beulens JW, Stolk RP, Navis G, Bakker SJ. Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc 2012;1:e002956. [PMID: 23316297 DOI: 10.1161/JAHA.112.002956] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Andreadou I, Efentakis P, Frenis K, Daiber A, Schulz R. Thiol-based redox-active proteins as cardioprotective therapeutic agents in cardiovascular diseases. Basic Res Cardiol 2021;116:44. [PMID: 34275052 DOI: 10.1007/s00395-021-00885-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Tang WH. Targeting endogenous antioxidants to prevent cardiovascular diseases. J Am Heart Assoc 2012;1:e005215. [PMID: 23316330 DOI: 10.1161/JAHA.112.005215] [Reference Citation Analysis]
3 Penzenstadler C, Zifko A, Jafarmadar M, Schulte J, Struck J, Stainer M, Kozlov A, Bahrami S. Organ-Specific Oxidative Events under Restrictive Versus Full Reperfusion Following Hemorrhagic Traumatic Shock in Rats. Molecules 2018;23:E2195. [PMID: 30200263 DOI: 10.3390/molecules23092195] [Reference Citation Analysis]
4 Jeong SJ, Park JG, Oh GT. Peroxiredoxins as Potential Targets for Cardiovascular Disease. Antioxidants (Basel) 2021;10:1244. [PMID: 34439492 DOI: 10.3390/antiox10081244] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Seyedsadjadi N, Grant R. The Potential Benefit of Monitoring Oxidative Stress and Inflammation in the Prevention of Non-Communicable Diseases (NCDs). Antioxidants (Basel) 2020;10:E15. [PMID: 33375428 DOI: 10.3390/antiox10010015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Brown DI, Griendling KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 2015;116:531-49. [PMID: 25634975 DOI: 10.1161/CIRCRESAHA.116.303584] [Cited by in Crossref: 283] [Cited by in F6Publishing: 151] [Article Influence: 40.4] [Reference Citation Analysis]
7 Mazloomi S, Sheikh N, Sanoee Farimani M, Pilehvari S. Association of Prx4, Total Oxidant Status, and Inflammatory Factors with Insulin Resistance in Polycystic Ovary Syndrome. Int J Endocrinol 2021;2021:9949753. [PMID: 34239559 DOI: 10.1155/2021/9949753] [Reference Citation Analysis]
8 Park MH, Jo M, Kim YR, Lee CK, Hong JT. Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol Ther 2016;163:1-23. [PMID: 27130805 DOI: 10.1016/j.pharmthera.2016.03.018] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 12.2] [Reference Citation Analysis]
9 Chanana P, Padhy G, Bhargava K, Arya R. Mutation in GNE Downregulates Peroxiredoxin IV Altering ER Redox Homeostasis. Neuromolecular Med 2017;19:525-40. [PMID: 28895049 DOI: 10.1007/s12017-017-8467-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
10 Vassalle C, Maltinti M, Sabatino L. Targeting Oxidative Stress for Disease Prevention and Therapy: Where Do We Stand, and Where Do We Go from Here. Molecules 2020;25:E2653. [PMID: 32517368 DOI: 10.3390/molecules25112653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
11 Gerrits EG, Alkhalaf A, Landman GW, van Hateren KJ, Groenier KH, Struck J, Schulte J, Gans RO, Bakker SJ, Kleefstra N, Bilo HJ. Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28). PLoS One 2014;9:e89719. [PMID: 24586984 DOI: 10.1371/journal.pone.0089719] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
12 Nuebel E, Manganas P, Tokatlidis K. Orphan proteins of unknown function in the mitochondrial intermembrane space proteome: New pathways and metabolic cross-talk. Biochim Biophys Acta 2016;1863:2613-23. [PMID: 27425144 DOI: 10.1016/j.bbamcr.2016.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
13 Abbasi A, Corpeleijn E, Gansevoort RT, Gans RO, Struck J, Schulte J, Hillege HL, van der Harst P, Stolk RP, Navis G, Bakker SJ. Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2014;57:1842-9. [PMID: 24893865 DOI: 10.1007/s00125-014-3278-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
14 Elko EA, Manuel AM, White S, Zito E, van der Vliet A, Anathy V, Janssen-Heininger YMW. Oxidation of peroxiredoxin-4 induces oligomerization and promotes interaction with proteins governing protein folding and endoplasmic reticulum stress. J Biol Chem 2021;296:100665. [PMID: 33895140 DOI: 10.1016/j.jbc.2021.100665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lowe FJ, Shen W, Zu J, Li J, Wang H, Zhang X, Zhong L. A novel autoantibody test for the detection of pre-neoplastic lung lesions. Mol Cancer 2014;13:78. [PMID: 24708840 DOI: 10.1186/1476-4598-13-78] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
16 Unuma K, Yoshikawa A, Aki T, Uemura K. Increased circulating peroxiredoxin-4 in sepsis model rats involves secretion from hepatocytes and is mitigated by GYY4137. J Toxicol Pathol 2019;32:305-10. [PMID: 31719759 DOI: 10.1293/tox.2019-0030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Yi Q, Meng C, Cai LB, Cui YG, Liu JY, Meng Y. Peroxiredoxin 4, a new oxidative stress marker in follicular fluid, may predict in vitro fertilization and embryo transfer outcomes. Ann Transl Med 2020;8:1049. [PMID: 33145268 DOI: 10.21037/atm-20-397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Forshaw TE, Reisz JA, Nelson KJ, Gumpena R, Lawson JR, Jönsson TJ, Wu H, Clodfelter JE, Johnson LC, Furdui CM, Lowther WT. Specificity of Human Sulfiredoxin for Reductant and Peroxiredoxin Oligomeric State. Antioxidants (Basel) 2021;10:946. [PMID: 34208049 DOI: 10.3390/antiox10060946] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 El Eter E, Al-Masri AA. Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus. Braz J Med Biol Res 2015;48:465-9. [PMID: 25742636 DOI: 10.1590/1414-431X20144142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
20 Schulman S, Bendapudi P, Sharda A, Chen V, Bellido-Martin L, Jasuja R, Furie BC, Flaumenhaft R, Furie B. Extracellular Thiol Isomerases and Their Role in Thrombus Formation. Antioxid Redox Signal 2016;24:1-15. [PMID: 26467859 DOI: 10.1089/ars.2015.6530] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]